
COMPASS Pathways (CMPS) Stock Forecast & Price Target
COMPASS Pathways (CMPS) Analyst Ratings
Bulls say
Compass Pathways is expected to have a successful launch of their COMP360 treatment due to promising trial results, increased commercial preparation, and the potential for a parallel DEA rescheduling. With a funded runway into 2028 and a targeted population of 4 million in the US alone, Compass Pathways is poised for potential success in the mental health biotechnology industry. Though risks such as clinical development, competition, and regulatory hurdles exist, the company's strong financial position and promising data make it a favorable investment.
Bears say
Compass Pathways is facing potential roadblocks in launching their drug, COMP360, as its lengthy treatment process may not be accepted by providers and patient demand for psychedelics is robust, leading to uncertain peak commercial potential. Furthermore, the company faces competition from other players in the emerging psychedelics market, and their late-stage PTSD program may not offer significant upside. This combined with a discounted cash flow analysis with a low terminal growth rate suggests a negative outlook for the company's stock.
This aggregate rating is based on analysts' research of COMPASS Pathways and is not a guaranteed prediction by Public.com or investment advice.
COMPASS Pathways (CMPS) Analyst Forecast & Price Prediction
Start investing in COMPASS Pathways (CMPS)
Order type
Buy in
Order amount
Est. shares
0 shares